Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), etiological agent of the coronavirus disease 2019 (COVID-19), is currently detected by reverse transcription followed by quantitative polymerase chain reaction (RT-qPCR) of its viral RNA genome. Within the available alternatives, One-Step procedures are preferred since they are fast and significantly decrease preanalytical errors, minimizing the risk of diagnostic errors.
Increasing the testing capacity and tracing contacts are essential steps to control the pandemic. However, high-cost commercial reagents subject to shortage and poor scalability have hindered the use of these technologies and their adoption for a wide population-scale testing, being even more critical in developing countries. In the current context, open-source initiatives have promoted global collaboration to promote accessible solutions for rapid local deployment. As a result, open protocols are being developed for the local production of SARS-CoV-2 diagnostics.
This work aimed to produce an open-source system for SARS-CoV-2 diagnostic tests in RNA clinical samples. We provide guidelines for standardizing an open One-Step RT-qPCR master mix using recombinant M-MLV reverse transcriptase together with either Pfu-Sso7d or Taq DNA polymerase. Both were tested on synthetic RNA and clinical samples, observing a good correlation when compared to commercial RT-qPCR kits. Nevertheless, the best results were obtained using M-MLV RT combined with Taq DNA polymerase in a probe-based RT-qPCR assay, allowing successful discrimination between positive and negative samples with accuracies comparable to a CDC-recommended commercial kit.
Here, we demonstrate that these open RT-qPCR systems can be successfully used to identify SARS-CoV-2 in clinical samples and potentially be implemented in any molecular diagnostic laboratory.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.protocols.io/view/recombinant-protein-expression-and-purification-of-bzusp6we
https://www.protocols.io/view/recombinant-expression-and-purification-of-codon-o-bsernbd6
https://www.protocols.io/view/recombinant-protein-expression-and-purification-of-bya3psgn
Funding Statement
This work was supported by the National Agency for Research and Development (ANID) through the ANID Millennium Science Initiative Program (ICN17_022), Fondo de Desarrollo de Areas Prioritarias (Center for Genome Regulation; ANID/FONDAP/15090007), Fondo de Desarrollo Cientifico y Tecnologico (FONDECYT 1201684 awarded to C.A. Ramirez-Sarmiento, FONDECYT Regular 1211218 to Fernan Federici, and FONDECYT 3190731 to Maira Rivera), and International Cooperation Program with Consejo Nacional de Ciencia, Tecnologia e Innovacion Tecnologica (ANID-CONCYTEC covbio0012 awarded to F. Federici and C.A. Ramirez-Sarmiento). This work was also supported by the National Institutes of Health NIAID training grant (Training Program in Immunology; T32-AI07405) awarded to A. J. Brown. P. Blazquez-Sanchez and J. Reyes were supported by ANID Doctoral Scholarships (21191979 and 21191684, respectively).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval for the use of biological samples for diagnostic tests was obtained from the Ethical Review Board of the Faculty of Medicine, Pontificia Universidad Catolica de Chile (code: 210105007). Informed consent was obtained from all participants and/or their legal guardians.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
